title: Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate.
abstract: OBJECTIVE
  To analyse pulmonary toxicity in psoriatic arthritis patients treated with weekly low-dose methotrexate.
  
  
  METHODS
  A transversal study was carried out to analyse the findings on chest x-rays and high resolution computed tomography, and the results of pulmonary function tests in 27 Caucasian psoriatic arthritis patients treated with weekly low-dose methotrexate. None of them had previous recognized interstitial lung disease.
  
  
  RESULTS
  The median age of the patient cohort was 50 years (range 24-70 years) and the sex ratio was 20M/7F. 17 patients had previously used other disease-modifying antirheumatic drugs. The mean weekly dose of methotrexate was 8.46 mg (range 5-15 mg), the average treatment period was 52 months (range 3-240 months), and the median cumulative dose was 2241 mg (range 300-6520 mg). High resolution computed tomography failed to show alveolar or interstitial involvement in any patient. Diffusing lung capacity for carbon monoxide was mildly altered only in 2 cases. Pulmonary function tests did not show differences between patients with and without recognized risk factors for developing methotrexate-associated lung toxicity identified in rheumatoid arthritis patients (old age, diabetes, hypoalbuminemia, previous use of disease modifying antirheumatic drugs).
  
  
  CONCLUSIONS
  In this cohort of 27 psoriatic arthritis patients methotrexate was not associated with pulmonary fibrosis evaluated by means of sensitive imaging findings and pulmonary function tests.
authors.affiliation: Rheumatology Unit, Hospital N.S. Aranzazu, San Sebastian, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Belzunegui
authors.forename: J J
authors.initials: JJ
authors.lastname: Intxausti
authors.forename: J R
authors.initials: JR
authors.lastname: De Dios
authors.forename: L
authors.initials: L
authors.lastname: López-Domínguez
authors.forename: R
authors.initials: R
authors.lastname: Queiro
authors.forename: C
authors.initials: C
authors.lastname: González
authors.forename: M
authors.initials: M
authors.lastname: Figueroa
mesh_terms: D000328:Adult; D000368:Aged; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D011658:Pulmonary Fibrosis / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D012129:Respiratory Function Tests; D014057:Tomography, X-Ray Computed
chemical_list: D018501:Antirheumatic Agents; D008727:Methotrexate